Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (1) Daumke, Oliver Prof. Dr. (2) Franke, Vedran Dr. (1) Hinz, Michael Dr. (1) Hübner, Norbert Prof. Dr. (1) Janz, Martin Dr. (4) Kolesnichenko, Marina Dr. (1) Patone, Giannino Dr. (1) Rocks, Oliver Dr. (1) Scheidereit, Claus Prof. Dr. (3) Wollert-Wulf, Brigitte (3) (-) Mathas, Stephan Dr. (9) (-) Selbach, Matthias Prof. Dr. (1) 1999 (1) 2000 (1) (-) 2001 (1) 2002 (5) 2003 (1) 2004 (2) 2005 (2) 2006 (4) 2007 (3) 2008 (4) 2009 (3) 2010 (3) 2011 (4) 2012 (1) (-) 2013 (1) 2014 (2) (-) 2015 (5) 2016 (2) 2017 (3) 2018 (1) (-) 2019 (2) 2020 (2) 2021 (3) 2022 (4) 2023 (7) 2024 (4) Anchored Signalling (1) Bioinformatics and Omics Data Science (1) Bioinformatics of RNA Structure and Transcriptome Regulation (1) (-) Biology of Malignant Lymphomas (9) Computational Regulatory Genomics (3) Developmental Biology / Signal Transduction (2) Genetics and Genomics of Cardiovascular Diseases (2) Genome Diversification & Integrity (1) Immune Regulation and Cancer (1) Mathematical Modelling of Cellular Processes (1) Molecular Immunology and Gene Therapy (2) Molecular Physiology of Somatic Sensation (1) Proteome Dynamics (23) Proteomics and Metabolomics (2) Proteomics and Molecular Mechanisms of Neurodegenerative Diseases (1) RNA Biology and Posttranscriptional Regulation (1) Structural Biology of Membrane-Associated Processes (2) Systems Biology of Gene Regulatory Elements (2) 9 Results: Active Filter: Mathas, Stephan Dr.Selbach, Matthias Prof. Dr.Biology of Malignant Lymphomas2001201320152019 Sort: Result score Newest to oldest Oldest to newest January 01, 2001 / Blood Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells M. Hinz P. Loeser S. Mathas D. Krappmann B. Dörken C. Scheidereit January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz May, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz March, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas April 02, 2013 / Structure Structural insights into the mechanism of GTPase activation in the GIMAP family D. Schwefel B.S. Arasu S.F. Marino B. Lamprecht K. Köchert E. Rosenbaum J. Eichhorst B. Wiesner J. Behlke O. Rocks S. Mathas O. Daumke June, 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer June 01, 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas March 28, 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert
January 01, 2001 / Blood Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells M. Hinz P. Loeser S. Mathas D. Krappmann B. Dörken C. Scheidereit
January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz
May, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
March, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
April 02, 2013 / Structure Structural insights into the mechanism of GTPase activation in the GIMAP family D. Schwefel B.S. Arasu S.F. Marino B. Lamprecht K. Köchert E. Rosenbaum J. Eichhorst B. Wiesner J. Behlke O. Rocks S. Mathas O. Daumke
June, 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer
March 28, 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit
April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert